| Tajana Kundacina, DO | |
|
1 E Main St Ste 100, Auburn, WA 98002-4905 | |
| (425) 690-3480 | |
| (425) 690-9480 |
| Full Name | Tajana Kundacina |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 1 E Main St Ste 100, Auburn, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275028664 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | OP61276240 (Washington) | Primary |
| Entity Name | Valley Medical Group-renton |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619209574 PECOS PAC ID: 4183753965 Enrollment ID: O20100604000113 |
News Archive
When doctors could be reached via telemedicine to decide whether a patient in a skilled nursing facility (SNF) should be hospitalized, 29% of the patients evaluated avoided a hospital visit, saving $1.55 million over the course of a year, according to results reported in the current issue of The American Journal of Managed Care.
As interest in concussion rates and prevention strategies at all levels continues to grow, one population that appears to have increasing head injury rates is collegiate football players.
Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.
Researchers have created a new approach for studying resistance to Neuraminidase Inhibitors (NI) in influenza.
› Verified 6 days ago
| Entity Name | Obhg Washington Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962729525 PECOS PAC ID: 0345364642 Enrollment ID: O20100823001087 |
News Archive
When doctors could be reached via telemedicine to decide whether a patient in a skilled nursing facility (SNF) should be hospitalized, 29% of the patients evaluated avoided a hospital visit, saving $1.55 million over the course of a year, according to results reported in the current issue of The American Journal of Managed Care.
As interest in concussion rates and prevention strategies at all levels continues to grow, one population that appears to have increasing head injury rates is collegiate football players.
Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.
Researchers have created a new approach for studying resistance to Neuraminidase Inhibitors (NI) in influenza.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tajana Kundacina, DO 1 E Main St Ste 100, Auburn, WA 98002-4905 Ph: (425) 690-3480 | Tajana Kundacina, DO 1 E Main St Ste 100, Auburn, WA 98002-4905 Ph: (425) 690-3480 |
News Archive
When doctors could be reached via telemedicine to decide whether a patient in a skilled nursing facility (SNF) should be hospitalized, 29% of the patients evaluated avoided a hospital visit, saving $1.55 million over the course of a year, according to results reported in the current issue of The American Journal of Managed Care.
As interest in concussion rates and prevention strategies at all levels continues to grow, one population that appears to have increasing head injury rates is collegiate football players.
Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.
Researchers have created a new approach for studying resistance to Neuraminidase Inhibitors (NI) in influenza.
› Verified 6 days ago
Olga Valieva, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 E Main St Ste 100, Auburn, WA 98002 Phone: 425-690-3480 Fax: 425-690-9480 | |
Victoria Hwang, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 East Main Street Suite 100, Auburn, WA 98002 Phone: 425-690-3480 Fax: 425-690-9480 | |
Amy K Atwood, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 E Main St, Suite 100, Auburn, WA 98002 Phone: 253-939-9654 Fax: 253-939-6549 | |
Yvonne A Yao, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 East Main St #360, Auburn, WA 98002 Phone: 253-545-5800 | |
Maria F Gutierrez-yach, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 202 N Division St, Ste 301, Auburn, WA 98001 Phone: 253-876-7990 | |
Caroline Huff Boerwinkle, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 E Main St Ste 100, Auburn, WA 98002 Phone: 425-690-3480 Fax: 425-690-9480 |